Breaking News Instant updates and real-time market news.

KALU

Kaiser Aluminum

$107.59 /

+2 (+1.89%)

16:31
04/23/19
04/23
16:31
04/23/19
16:31

Kaiser Aluminum reports Q1 adjusted EPS $1.85, consensus $1.79

Reports Q1 revenue $395M, consensus $404.05M. "Continuing the positive trend from the second half 2018, we reported strong first quarter 2019 results. Improving aerospace demand and non-contract value added pricing drove strong results in the quarter, partially offset by approximately $5 million of cost inefficiencies at our Trentwood facility, a combination of unplanned equipment downtime in the finishing operations and purchased rolling ingot costs necessitated by our planned casting furnace rebuilds," said Jack A. Hockema, Chairman and Chief Executive Officer.

  • 24

    Apr

KALU Kaiser Aluminum
$107.59 /

+2 (+1.89%)

10/23/18 Jefferies
Jefferies upgrades Kaiser Aluminum to Buy following recent selloff
10/23/18 Jefferies
Kaiser Aluminum upgraded to Buy from Hold at Jefferies
08/13/18 Goldman Sachs
Kaiser Aluminum downgraded to Sell from Neutral at Goldman Sachs
07/16/18 Jefferies
Kaiser Aluminum initiated with a Hold at Jefferies

TODAY'S FREE FLY STORIES

Upgrade
Valvoline upgraded to Overweight from Neutral at JPMorgan » 04:46
08/05/20
08/05
04:46
08/05/20
04:46
VVV

Valvoline

$20.91 /

-0.17 (-0.81%)

JPMorgan analyst Jeffrey…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VVV Valvoline
$20.91 /

-0.17 (-0.81%)

VVV Valvoline
$20.91 /

-0.17 (-0.81%)

06/04/20 SunTrust
Valvoline upgraded to Buy from Hold at SunTrust
06/04/20 SunTrust
Valvoline upgraded to Buy from Hold at SunTrust
04/20/20 SunTrust
Valvoline price target lowered to $16 from $23 at SunTrust
03/23/20 Jefferies
Jefferies downgrades 10 'lower conviction' Chemicals stocks to Hold
VVV Valvoline
$20.91 /

-0.17 (-0.81%)

VVV Valvoline
$20.91 /

-0.17 (-0.81%)

Downgrade
AssetMark Financial downgraded to Neutral from Overweight at JPMorgan » 04:46
08/05/20
08/05
04:46
08/05/20
04:46
AMK

AssetMark Financial

$27.20 /

-0.49 (-1.77%)

JPMorgan analyst Kenneth…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMK AssetMark Financial
$27.20 /

-0.49 (-1.77%)

AMK AssetMark Financial
$27.20 /

-0.49 (-1.77%)

07/15/20 Raymond James
AssetMark Financial price target raised to $31 from $27 at Raymond James
04/14/20 Raymond James
AssetMark Financial price target lowered to $26 from $29 at Raymond James
03/13/20 Raymond James
AssetMark Financial price target lowered to $29 from $33 at Raymond James
01/16/20 Raymond James
AssetMark Financial price target raised to $34 from $32 at Raymond James
AMK AssetMark Financial
$27.20 /

-0.49 (-1.77%)

AMK AssetMark Financial
$27.20 /

-0.49 (-1.77%)

Upgrade
Novavax upgraded to Overweight from Neutral at JPMorgan » 04:45
08/05/20
08/05
04:45
08/05/20
04:45
NVAX

Novavax

$157.30 /

+1.13 (+0.72%)

JPMorgan analyst Eric…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NVAX Novavax
$157.30 /

+1.13 (+0.72%)

NVAX Novavax
$157.30 /

+1.13 (+0.72%)

07/16/20 B. Riley FBR
Novavax price target raised to $155 from $106 at B. Riley FBR
07/16/20 H.C. Wainwright
Novavax price target raised to $132 from $101 at H.C. Wainwright
07/08/20
Fly Intel: Top five analyst downgrades
07/08/20 Ladenburg
Novavax downgraded to Neutral from Buy at Ladenburg
NVAX Novavax
$157.30 /

+1.13 (+0.72%)

NVAX Novavax
$157.30 /

+1.13 (+0.72%)

NVAX Novavax
$157.30 /

+1.13 (+0.72%)

NVAX Novavax
$157.30 /

+1.13 (+0.72%)

Upgrade
BMC Stock Holdings upgraded to Buy from Neutral at B. Riley FBR » 04:44
08/05/20
08/05
04:44
08/05/20
04:44
BMCH

BMC Stock Holdings

$30.30 /

+1.82 (+6.39%)

B. Riley FBR analyst Alex…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BMCH BMC Stock Holdings
$30.30 /

+1.82 (+6.39%)

BMCH BMC Stock Holdings
$30.30 /

+1.82 (+6.39%)

08/04/20 Wedbush
BMC Stock Holdings upgraded to Outperform at Wedbush
08/04/20 Wedbush
BMC Stock Holdings upgraded to Outperform from Neutral at Wedbush
07/15/20 B. Riley FBR
BMC Stock Holdings price target raised to $25 from $23 at B. Riley FBR
06/18/20
Fly Intel: Top five analyst upgrades
BMCH BMC Stock Holdings
$30.30 /

+1.82 (+6.39%)

Downgrade
Fresenius SE downgraded to Underperform from Hold at Jefferies » 04:43
08/05/20
08/05
04:43
08/05/20
04:43
FSNUY

Fresenius SE

$0.00 /

+ (+0.00%)

Jefferies analyst James…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FSNUY Fresenius SE
$0.00 /

+ (+0.00%)

07/24/20 Deutsche Bank
Deutsche Bank backs Buy on Fresenius ahead of Q2 results
06/17/20 UBS
Fresenius SE price target lowered to EUR 47 from EUR 49 at UBS
06/01/20 Barclays
Fresenius SE price target raised to EUR 53 from EUR 51 at Barclays
05/20/20 Morgan Stanley
Fresenius SE upgraded to Overweight from Equal Weight at Morgan Stanley
FSNUY Fresenius SE
$0.00 /

+ (+0.00%)

Downgrade
Fresenius Medical downgraded to Hold from Buy at Jefferies » 04:41
08/05/20
08/05
04:41
08/05/20
04:41
FMS

Fresenius Medical

$44.28 /

-0.475 (-1.06%)

Jefferies analyst James…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FMS Fresenius Medical
$44.28 /

-0.475 (-1.06%)

FMS Fresenius Medical
$44.28 /

-0.475 (-1.06%)

07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
07/24/20 Deutsche Bank
Deutsche Bank backs Buy on Fresenius Medical ahead of Q2 results
07/17/20 JPMorgan
Fresenius Medical price target raised to EUR 94.80 from EUR 84.20 at JPMorgan
06/01/20 Barclays
Fresenius Medical price target raised to EUR 88 from EUR 81 at Barclays
FMS Fresenius Medical
$44.28 /

-0.475 (-1.06%)

General news
FX Action: USD-CAD has ebbed to its lowest level since February » 03:50
08/05/20
08/05
03:50
08/05/20
03:50

FX Action: USD-CAD has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
FX Update: The dollar has remained soft » 03:35
08/05/20
08/05
03:35
08/05/20
03:35

FX Update: The dollar has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
Asian Market Update: » 01:55
08/05/20
08/05
01:55
08/05/20
01:55

Asian Market Update: The…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Syndicate
Immunic 5M share Secondary priced at $18.00 » 23:36
08/04/20
08/04
23:36
08/04/20
23:36
IMUX

Immunic

$19.38 /

-2.59 (-11.79%)

SVB Leerink and Piper…

SVB Leerink and Piper Sandler acted as joint book running managers for the offering.

ShowHide Related Items >><<
IMUX Immunic
$19.38 /

-2.59 (-11.79%)

IMUX Immunic
$19.38 /

-2.59 (-11.79%)

08/03/20 BMO Capital
Immunic price target raised to $61 from $40 at BMO Capital
08/03/20 H.C. Wainwright
Immunic price target raised to $60 from $45 at H.C. Wainwright
07/20/20
Fly Intel: Top five analyst initiations
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
IMUX Immunic
$19.38 /

-2.59 (-11.79%)

  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$19.38 /

-2.59 (-11.79%)

Syndicate
BigCommerce 9.02M share IPO priced at $24.00 » 23:34
08/04/20
08/04
23:34
08/04/20
23:34
BIGC

BigCommerce

$0.00 /

+ (+0.00%)

The deal priced above the…

The deal priced above the range of $21.00-$23.00. Morgan Stanley, Barclays, Jefferies and KeyBanc acted as joint book running managers for the offering.

ShowHide Related Items >><<
  • 05
    Aug
Syndicate
Rackspace Technology 33.5M share IPO priced at $21.00 » 23:28
08/04/20
08/04
23:28
08/04/20
23:28
RXT

Rackspace Technology

$0.00 /

+ (+0.00%)

The deal range was…

The deal range was $21.00-$24.00. Goldman Sachs, Citi and JPMorgan acted as joint book running managers for the offering.

ShowHide Related Items >><<
  • 05
    Aug
RXT Rackspace Technology
$0.00 /

+ (+0.00%)

Recommendations
BioMarin price target raised to $133 from $120 at Piper Sandler » 20:39
08/04/20
08/04
20:39
08/04/20
20:39
BMRN

BioMarin

$119.65 /

-2.44 (-2.00%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond raised the firm's price target on BioMarin to $133 from $120 and keeps an Overweight rating on the shares following a sales and earnings beat in Q2 that was mainly driven by stronger than expected results for the PKU franchise. Following the report, Raymond remains a buyer of the shares ahead of the PDUFA date on August 21 for Roctavian, noting that management said they remain confident in timely U.S. and EU approvals of the drug.

ShowHide Related Items >><<
BMRN BioMarin
$119.65 /

-2.44 (-2.00%)

BMRN BioMarin
$119.65 /

-2.44 (-2.00%)

07/24/20 Baird
BioMarin price target raised to $140 from $125 at Baird
07/08/20 Morgan Stanley
Morgan Stanley cuts BioMarin to Equal Weight with pipeline seen better priced in
07/08/20 Morgan Stanley
BioMarin downgraded to Equal Weight from Overweight at Morgan Stanley
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
BMRN BioMarin
$119.65 /

-2.44 (-2.00%)

BMRN BioMarin
$119.65 /

-2.44 (-2.00%)

BMRN BioMarin
$119.65 /

-2.44 (-2.00%)

Recommendations
Piper Sandler likes setup for Aptose Biosciences into ASH meeting » 20:34
08/04/20
08/04
20:34
08/04/20
20:34
APTO

Aptose Biosciences

$5.14 /

-0.075 (-1.44%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren said he expects a comprehensive update from Aptose Biosciences on both the company's Phase I dose escalation trial for 806 in r/r B cell malignancies and the Phase I r/r AML trial at the American Society of Hematology meeting. He likes the setup for the stock going into the ASH meeting given the potential to see first 806 responses in both trials, said the analyst, who keeps an Overweight rating and $10 price target on Aptose following the company's quarterly report.

ShowHide Related Items >><<
APTO Aptose Biosciences
$5.14 /

-0.075 (-1.44%)

APTO Aptose Biosciences
$5.14 /

-0.075 (-1.44%)

06/12/20 Piper Sandler
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler
06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
APTO Aptose Biosciences
$5.14 /

-0.075 (-1.44%)

  • 16
    Jul
  • 17
    Dec
APTO Aptose Biosciences
$5.14 /

-0.075 (-1.44%)

Recommendations
Piper Sandler remain buyers of Deciphera following 'massive' Qinlock beat » 20:26
08/04/20
08/04
20:26
08/04/20
20:26
DCPH

Deciphera

$48.51 /

-0.95 (-1.92%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond noted that Deciphera posted Q2 sales of Qinlock of $4.8M in only six weeks, which he notes was well ahead of the consensus forecast of $700,000. Raymond, who has raised his Q3 and FY20 Qinlock sales estimates to $8M and $29M, respectively, remains a buyer of Deciphera following the "massive" beat for the drug following its launch. He maintains an Overweight rating on Deciphera with a $75 price target.

ShowHide Related Items >><<
DCPH Deciphera
$48.51 /

-0.95 (-1.92%)

DCPH Deciphera
$48.51 /

-0.95 (-1.92%)

07/07/20 Piper Sandler
Deciphera estimates raised on 'exceedingly bullish' survey at Piper Sandler
05/18/20 Truist
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
DCPH Deciphera
$48.51 /

-0.95 (-1.92%)

  • 14
    Feb
  • 15
    Aug
DCPH Deciphera
$48.51 /

-0.95 (-1.92%)

Recommendations
Sarepta price target lowered to $200 from $206 at Piper Sandler » 20:02
08/04/20
08/04
20:02
08/04/20
20:02
SRPT

Sarepta

$156.68 /

-1.67 (-1.05%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren lowered the firm's price target on Sarepta to $200 from $206 and keeps an Overweight rating on the shares. The analyst fine tuned estimates ahead of the company's quarterly results tomorrow. The launch of Vyondys has been slightly impacted by COVID-19 in some locations as the first few infusions require a hospital setting for extensive monitoring, Van Buren tells investors in a research note.

ShowHide Related Items >><<
SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

Upgrade
Palo Alto Networks upgraded to Buy from Neutral at BTIG » 20:01
08/04/20
08/04
20:01
08/04/20
20:01
PANW

Palo Alto Networks

$254.77 /

+0.365 (+0.14%)

BTIG analyst Gray Powell…

BTIG analyst Gray Powell upgraded Palo Alto Networks to Buy from Neutral with a $313 price target. The analyst says his most recent channel checks continue to be positive. He heard that Palo Alto's sales execution on the core firewall side of the business has improved and that demand remained solid through July. The commentary indicates that sales of Prisma Access are gaining momentum, Powell tells investors in a research note. Further, the analyst also heard of improved commentary in the U.S. Fed with four large deals closing in late July. He now has a greater degree of confidence in Palo Alto's ability to exceed Street estimates in fiscal Q4 and maintain growth in the high teens in the second half of 2020.

ShowHide Related Items >><<
PANW Palo Alto Networks
$254.77 /

+0.365 (+0.14%)

PANW Palo Alto Networks
$254.77 /

+0.365 (+0.14%)

07/28/20 Jefferies
Palo Alto Networks price target raised to $300 from $275 at Jefferies
07/09/20 Citi
Citi recommends overweight Palo Alto Networks, underweight Fortinet pair trade
06/04/20 Cleveland Research
Palo Alto momentum extending into Q4, says Cleveland Research
05/22/20 BMO Capital
Palo Alto Networks price target raised to $260 from $230 at BMO Capital
PANW Palo Alto Networks
$254.77 /

+0.365 (+0.14%)

PANW Palo Alto Networks
$254.77 /

+0.365 (+0.14%)

PANW Palo Alto Networks
$254.77 /

+0.365 (+0.14%)

PANW Palo Alto Networks
$254.77 /

+0.365 (+0.14%)

Downgrade
Bluegreen Vacations downgraded to Hold from Buy at Stifel » 19:58
08/04/20
08/04
19:58
08/04/20
19:58
BXG

Bluegreen Vacations

$7.71 /

+0.22 (+2.94%)

Stifel analyst Simon…

Stifel analyst Simon Yarmak downgraded Bluegreen Vacations to Hold from Buy with an unchanged price target of $7.50. The analyst cites valuation for the downgrade with the shares up 41% quarter-to-date and exceeding the price target.

ShowHide Related Items >><<
BXG Bluegreen Vacations
$7.71 /

+0.22 (+2.94%)

Initiation
Range Resources assumed with an Underperform at Credit Suisse » 19:56
08/04/20
08/04
19:56
08/04/20
19:56
RRC

Range Resources

$7.68 /

+0.48 (+6.67%)

Credit Suisse analyst…

Credit Suisse analyst William Jan assumed coverage of Range Resources with an Underperform rating and $4 price target. The analyst made no changes to the firm's ratings, target prices or estimates in the Oil and Gas Exploration and Production sector.

ShowHide Related Items >><<
RRC Range Resources
$7.68 /

+0.48 (+6.67%)

RRC Range Resources
$7.68 /

+0.48 (+6.67%)

07/22/20 Mizuho
Mizuho starts Range Resources at Neutral on uncertain outlook
07/22/20 Mizuho
Range Resources initiated with a Neutral at Mizuho
07/09/20 MKM Partners
Range Resources upgraded to Buy from Neutral at MKM Partners
07/09/20 MKM Partners
Range Resources upgraded to Buy from Neutral at MKM Partners
RRC Range Resources
$7.68 /

+0.48 (+6.67%)

RRC Range Resources
$7.68 /

+0.48 (+6.67%)

RRC Range Resources
$7.68 /

+0.48 (+6.67%)

RRC Range Resources
$7.68 /

+0.48 (+6.67%)

Initiation
Cabot Oil & Gas assumed with a Neutral at Credit Suisse » 19:56
08/04/20
08/04
19:56
08/04/20
19:56
COG

Cabot Oil & Gas

$19.64 /

+0.51 (+2.67%)

Credit Suisse analyst…

Credit Suisse analyst William Janela assumed coverage of Cabot Oil & Gas with a Neutral rating and $21 price target. The analyst made no changes to the firm's ratings, target prices or estimates in the Oil and Gas Exploration and Production sector.

ShowHide Related Items >><<
COG Cabot Oil & Gas
$19.64 /

+0.51 (+2.67%)

COG Cabot Oil & Gas
$19.64 /

+0.51 (+2.67%)

07/23/20 Mizuho
Cabot Oil & Gas initiated with Neutral on valuation at Mizuho
07/22/20 Mizuho
Cabot Oil & Gas initiated with a Neutral at Mizuho
06/15/20 KeyBanc
KeyBanc sees 'slightly negative' reaction in Cabot shares from suit
06/01/20 Stifel
Cabot Oil & Gas downgraded to Sell from Hold at Stifel
COG Cabot Oil & Gas
$19.64 /

+0.51 (+2.67%)

COG Cabot Oil & Gas
$19.64 /

+0.51 (+2.67%)

COG Cabot Oil & Gas
$19.64 /

+0.51 (+2.67%)

Initiation
Diamondback Energy assumed with an Outperform at Credit Suisse » 19:55
08/04/20
08/04
19:55
08/04/20
19:55
FANG

Diamondback Energy

$41.06 /

+1.04 (+2.60%)

Credit Suisse analyst…

Credit Suisse analyst William Janela assumed coverage of Diamondback Energy with an Outperform rating and $57 price target. The analyst made no changes to the firm's ratings, target prices or estimates in the Oil and Gas Exploration and Production sector.

ShowHide Related Items >><<
FANG Diamondback Energy
$41.06 /

+1.04 (+2.60%)

FANG Diamondback Energy
$41.06 /

+1.04 (+2.60%)

07/27/20 Seaport Global
Diamondback Energy initiated with a Buy at Seaport Global
07/21/20 Piper Sandler
Diamondback Energy upgraded to Overweight from Neutral at Piper Sandler
07/20/20 Northland
Diamondback Energy price target raised to $50 from $45 at Northland
07/16/20 Imperial Capital
Diamondback Energy price target lowered to $55 from $70 at Imperial Capital
FANG Diamondback Energy
$41.06 /

+1.04 (+2.60%)

FANG Diamondback Energy
$41.06 /

+1.04 (+2.60%)

FANG Diamondback Energy
$41.06 /

+1.04 (+2.60%)

FANG Diamondback Energy
$41.06 /

+1.04 (+2.60%)

Initiation
Ovintiv assumed with a Neutral at Credit Suisse » 19:53
08/04/20
08/04
19:53
08/04/20
19:53
OVV

Ovintiv

$10.50 /

+0.605 (+6.11%)

Credit Suisse analyst…

Credit Suisse analyst William Janela assumed coverage of Ovintiv with a Neutral rating and $11 price target. The analyst made no changes to the firm's ratings, target prices or estimates in the Oil and Gas Exploration and Production sector.

ShowHide Related Items >><<
OVV Ovintiv
$10.50 /

+0.605 (+6.11%)

OVV Ovintiv
$10.50 /

+0.605 (+6.11%)

07/15/20 Wolfe Research
Ovintiv upgraded to Peer Perform from Underperform at Wolfe Research
06/29/20 BMO Capital
Ovintiv upgraded to Outperform from Market Perform at BMO Capital
06/19/20 Truist
Ovintiv price target raised to $12 from $7 at SunTrust
06/19/20 Mizuho
Ovintiv upgraded to Neutral from Underperform at Mizuho
OVV Ovintiv
$10.50 /

+0.605 (+6.11%)

OVV Ovintiv
$10.50 /

+0.605 (+6.11%)

OVV Ovintiv
$10.50 /

+0.605 (+6.11%)

OVV Ovintiv
$10.50 /

+0.605 (+6.11%)

Initiation
Pioneer Natural assumed with an Outperform at Credit Suisse » 19:53
08/04/20
08/04
19:53
08/04/20
19:53
PXD

Pioneer Natural

$99.51 /

+1.665 (+1.70%)

Credit Suisse analyst…

Credit Suisse analyst William Janela assumed coverage of Pioneer Natural with an Outperform rating and $115 price target. The analyst made no changes to the firm's ratings, target prices or estimates in the Oil and Gas Exploration and Production sector.

ShowHide Related Items >><<
PXD Pioneer Natural
$99.51 /

+1.665 (+1.70%)

PXD Pioneer Natural
$99.51 /

+1.665 (+1.70%)

07/20/20 Raymond James
Pioneer Natural upgraded to Strong Buy from Outperform at Raymond James
07/20/20 Raymond James
Pioneer Natural upgraded to Strong Buy from Outperform at Raymond James
06/25/20 Truist
Pioneer Natural upgraded to Buy from Hold at SunTrust
06/25/20 Truist
Pioneer Natural upgraded to Buy from Hold at SunTrust
PXD Pioneer Natural
$99.51 /

+1.665 (+1.70%)

PXD Pioneer Natural
$99.51 /

+1.665 (+1.70%)

PXD Pioneer Natural
$99.51 /

+1.665 (+1.70%)

PXD Pioneer Natural
$99.51 /

+1.665 (+1.70%)

Initiation
Concho Resources assumed with an Outperform at Credit Suisse » 19:53
08/04/20
08/04
19:53
08/04/20
19:53
CXO

Concho Resources

$51.43 /

+0.64 (+1.26%)

Credit Suisse analyst…

Credit Suisse analyst William Janela assumed coverage of Concho Resources with an Outperform rating and $70 price target. The analyst made no changes to the firm's ratings, target prices or estimates in the Oil and Gas Exploration and Production sector.

ShowHide Related Items >><<
CXO Concho Resources
$51.43 /

+0.64 (+1.26%)

CXO Concho Resources
$51.43 /

+0.64 (+1.26%)

07/28/20 Truist
Concho Resources upgraded to Buy from Hold at SunTrust
07/27/20 Seaport Global
Concho Resources initiated with a Buy at Seaport Global
07/20/20 Raymond James
Concho Resources upgraded to Strong Buy from Outperform at Raymond James
07/20/20 Raymond James
Concho Resources upgraded to Strong Buy from Outperform at Raymond James
CXO Concho Resources
$51.43 /

+0.64 (+1.26%)

CXO Concho Resources
$51.43 /

+0.64 (+1.26%)

CXO Concho Resources
$51.43 /

+0.64 (+1.26%)

CXO Concho Resources
$51.43 /

+0.64 (+1.26%)

Initiation
EOG Resources assumed with an Outperform at Credit Suisse » 19:51
08/04/20
08/04
19:51
08/04/20
19:51
EOG

EOG Resources

$48.43 /

+2.07 (+4.47%)

Credit Suisse analyst…

Credit Suisse analyst William Janela assumed coverage of EOG Resources with an Outperform rating and $65 price target. The analyst made no changes to the firm's ratings, target prices or estimates in the Oil and Gas Exploration and Production sector.

ShowHide Related Items >><<
EOG EOG Resources
$48.43 /

+2.07 (+4.47%)

EOG EOG Resources
$48.43 /

+2.07 (+4.47%)

07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 JPMorgan
EOG Resources downgraded on federal acreage risk at JPMorgan
07/23/20 JPMorgan
EOG Resources downgraded to Neutral from Overweight at JPMorgan
07/15/20 Wolfe Research
EOG Resources downgraded to Peer Perform from Outperform at Wolfe Research
EOG EOG Resources
$48.43 /

+2.07 (+4.47%)

EOG EOG Resources
$48.43 /

+2.07 (+4.47%)

EOG EOG Resources
$48.43 /

+2.07 (+4.47%)

EOG EOG Resources
$48.43 /

+2.07 (+4.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.